tert-butyl 1-(3-fluorophenyl)hydrazinecarboxylate | 1159589-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 1-(3-fluorophenyl)hydrazinecarboxylate
• 英文别名: tert-butyl N-amino-N-(3-fluorophenyl)carbamate
• CAS: 1159589-44-2
• 化学式: C₁₁H₁₅FN₂O₂
• 分子量: 226.251
• InChiKey: LIJQAVNXLGYIPS-UHFFFAOYSA-N

物化性质

• 沸点：
  306.8±44.0 °C(predicted)
• 密度：
  1.201±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  肼基甲酸叔丁酯 、 间氟碘苯 在 copper(l) iodide 、 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 4.0h， 以80%的产率得到tert-butyl 1-(3-fluorophenyl)hydrazinecarboxylate
  参考文献：
  名称：

  CuI / 4-羟基-1-脯氨酸是一种更有效的催化体系，用于将芳族溴化物与N- Boc肼和氨水偶联

  摘要：

  CuI / 4-羟基-1-脯氨酸催化的芳基溴化物与N- Boc肼的偶合反应在DMSO中于80°C进行，得到N-芳基酰肼。当使用芳基碘化物时，该反应在50℃下完成并且不需要配体。在CuI / 4-羟基-1-脯氨酸的催化下，氨水与芳基溴化物的偶联反应在50℃下顺利进行，得到伯芳基胺。在这种情况下，发现K 2 CO 3是比Cs 2 CO 3更好的碱。这些过程允许组装N带有多种官能团的-芳基酰肼和伯芳基胺包括羟基，胺基，三氟甲基，酯基，硝基和酮。

  DOI：

  10.1021/jo9006738

文献信息

• [EN] HISTONE DEACETYLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE DÉACÉTYLASE
  申请人：REPLIGEN CORP

  公开号：WO2012118782A1

  公开（公告）日：2012-09-07

  This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).

  这项发明涉及通常抑制组蛋白去乙酰化酶（HDAC）酶（例如，HDAC1、HDAC2和HDAC3）。
• Histone Deacetylase Inhibitors
  申请人：Repligen Corporation

  公开号：US20130317003A1

  公开（公告）日：2013-11-28

  This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).

  这项发明通常涉及抑制组蛋白去乙酰化酶（“HDAC”）酶（例如，HDAC1、HDAC2和HDAC3）。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE-DÉSACÉTYLASES
  申请人：BROAD INST INC

  公开号：WO2014018979A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting β-cells and improving insulin resistence. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation. Compounds of the invention are useful for treating, alleviating, and/or preventing various conditions, including for example, a metabolic disorder such as type 1 or type 2 diabetes, dyslipidemias, lipodystrophies, liver disease associated with metabolic syndrome, polycystic ovarian syndrome, or obesity; inflammatory disease; neurological disorder; a memory or cognitive function disorder/impairment; an extinction learning disorder; fungal disease or infection; viral disease or infection such as HIV; hematological disease; liver disease; lysosomal storage disease; or neoplastic disease in humans or animals.

  本发明涉及式(I)的化合物或其药学上可接受的盐、水合物、溶剂合物或前药，其中X1、X2、X3、X4、X5、W1、W2、W3和W4如所述。本发明一般涉及组织脱乙酰化酶抑制剂以及制备和使用它们的方法。在一个方面，该发明涉及选择性HDAC3抑制剂，可用于保护β细胞并改善胰岛素抵抗。选择性HDAC3抑制剂还可用于促进认知功能，增强学习和记忆形成。本发明的化合物可用于治疗、缓解和/或预防各种疾病，例如代谢紊乱，如1型或2型糖尿病、血脂异常、脂肪萎缩、与代谢综合征相关的肝病、多囊卵巢综合征或肥胖症；炎症性疾病；神经系统疾病；记忆或认知功能障碍；消除学习障碍；真菌疾病或感染；病毒性疾病或感染，如艾滋病病毒；血液病；肝病；溶酶体贮积病；或人类或动物的肿瘤性疾病。
• MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Chen Hui-Ju

  公开号：US20120101031A1

  公开（公告）日：2012-04-26

  The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

  本发明涉及新型大环化合物及使用该大环化合物治疗需要该疗法的丙型肝炎感染患者的方法。本发明还涉及包含本发明化合物或其药学上可接受的盐、酯或前药，与药学上可接受的载体或赋形剂组合的制药组合物。
• Inhibitors of Histone Deacetylase
  申请人：The Broad Institute, Inc.

  公开号：US20140080800A1

  公开（公告）日：2014-03-20

  The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R 2a , R 2b , R 2c , R 5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

  本发明涉及式（I）的化合物：或其药学上可接受的盐、水合物、溶剂合物或前药，其中U、J、V、X、R2a、R2b、R2c、R5和t如本文所述。本发明通常涉及组织脱乙酰化酶抑制剂及其制备和使用方法。这些化合物有助于促进认知功能和增强学习和记忆形成。此外，这些化合物对于治疗、缓解和/或预防各种疾病有用，包括但不限于神经系统疾病、记忆和认知功能障碍、消退学习障碍、真菌病和感染、炎症性疾病、血液病和动物的肿瘤疾病。